GEVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Synageva BioPharma Corp's quarterly additional paid-in capital increased from Dec. 2013 ($684.47 Mil) to Mar. 2014 ($891.74 Mil) and increased from Mar. 2014 ($891.74 Mil) to Jun. 2014 ($901.54 Mil).
Synageva BioPharma Corp's annual additional paid-in capital increased from Dec. 2011 ($189.87 Mil) to Dec. 2012 ($388.94 Mil) and increased from Dec. 2012 ($388.94 Mil) to Dec. 2013 ($684.47 Mil).
Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.
Additional Paid-In Capital is calculated as
|Additional Paid-In Capital||=||(Issue Price||-||Par Value)||*||Shares Outstanding|
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
Synageva BioPharma Corp Annual Data
Synageva BioPharma Corp Quarterly Data